Clinical and epidemiological aspects of chronic myeloproliferative diseases in the RS (Ya)
https://doi.org/10.25789/YMJ.2019.67.10
Abstract
The authors made the analysis of the clinical features and epidemiology of chronic myeloproliferative diseases in the Republic Sakha (Yakutia). The results of research demonstrated an increase of disease incidence in 2015-2016, high frequency of thrombotic complications among people younger than 60 years and the prevalence of the latent onset of the disease. The average time from thrombosis onset to disease diagnosis was 1 year. Arterial thrombosis - that is acute disorders of cerebral circulation and myocardial infarction - occurred most often. During follow up 19.4% of patients have developed re-thrombosis.
About the Authors
T. N. Aleksandrova
Republican Hospital No. 1 - National Centre of Medicine
Russian Federation
Russian Federation
Aleksandrova Tuiara Nikonovna – hematologist, junior researcher of the laboratory of heritable pathology
Yakutsk
I. I. Mulina
Republican Hospital No. 1 - National Centre of Medicine
Russian Federation
Russian Federation
Mulina Inna Ivanovna – Head of the Department of hematology
Yakutsk
V. N. Yadrikhinskaya
North-Eastern Federal University
Russian Federation
Russian Federation
Yadrikhinskaya Vera Nikolaevna – candidate of medical sciences, associate professor of department «Hospital therapy, professional diseases, clinical pharmacology» Medical Institute
I. E. Solovieva
Republican Hospital No. 1 - National Centre of Medicine
Russian Federation
Russian Federation
Solovieva Irina Eremeevna – hematologist
Yakutsk
L. D. Terekhova
Republican Hospital No. 1 - National Centre of Medicine
Russian Federation
Russian Federation
Terekhova Lena Dmitrievna – hematologist
Yakutsk
N. I. Pavlova
Yakut science Centre of the complex medical problems
Russian Federation
Russian Federation
Pavlova Nadezhda Ivanovna – PhD, temporary acting chief scientific officer - head of the laboratory of heritable pathology
Kh. A. Kurtanov
Yakut science Centre of the complex medical problems
Russian Federation
Russian Federation
Kurtanov Khariton Alekseevich – PhD, Chief Scientific Officer - Head of the Department of Molecular Genetics
Tel.: +7 (914) 106 00 30
References
1. Abdulkadyrov K.M. All we know about polycythemia vera: literature review and own experience / K.M. Abdulkadyrov, V.A. Shuvaev, I.S. Martynkevich // Oncohematology. – 2015. – Vol.10, №3. – P.28-42.DOI: 10.17650/1818-8346-2015-10-3-28-42.
2. Genetic markers of hereditary thrombophilia and risk of thrombotic complications in patients with polycythemia vera / D.I. Shikhbabaeva, L.B. Polushkina, V.A. Shuvaev [et al.] // Clinical oncohematology. – 2017. – Vol.1, №1. P.85-92.DOI: 10.21320/2500-2139-2017-10-1-85-92.
3. Melikyan A.L. Biology of myeloid malignancies / A.L. Melikyan, I.N. Subortseva // Clinical oncohematology. – 2016.– Vol.4, №3. – P.314-325. DOI: 10.21320/2500-2139-2016-9-3-314-325.
4. Tanashyan M.M. Myeloproliferative diseases and ischemic stroke / M.M. Tanashyan, P.I. Kusnetsova, O.V. Lagoda [et al.] // Annals of clinical and experimental neurology. – 2014. – Vol.8, №2. – Р.41-45.
5. Tanashyan M.M. Certain aspects of stroke prevention in patients with myeloproliferative diseases / M.M. Tanashyan, P.I. Kuznetsova, А.А. Raskurazhev // Neurology. – 2017. – Vol.4, № 1. – P.40-43.
6. Molecular genetic markers and clinical characteristics of essential thrombocythemia / A.A. Shernyakova, I.S. Masrtynkevich, V.A. Shuvaev [et al.] // Clinical oncohematology. – 2017. – V.10, №3. – P.402-408.DOI: 10.17650/1818-8346-2017-12-2-30-38.
7. Duangnapasatit D. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms / D. Duangnapasatit, E. Rattarittamrong, T. Rattanathammethee // Asian Pac J Cancer Prev. 2015. Vol.16, №12. – P5013-5018. DOI: 10.7314/APJCP.2015.16.12.5013.
8. Moulard O. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union / O. Moulard, J. 0Mehta, J. Fryzek [et al.] // Eur J Haematol. – 2014. – Vol.92, №4.– P.289-297. doi: 10.1111/ejh.12256. DOI: 10.1111/ejh.12256.
9. Arellano-Rodrigo E. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status / E. Arellano-Rodrigo, A. Alvarez-Larran, JC Reverter // Haematologica. – 2006. – Vol.91, - №2.– P.169-175.
10. Xavier S.G. JAK2V617F mutation in patients with splanchnic vein thrombosis / S.G. Xavier, T. Gadelha, G Pimenta // Dig Dis Sci. – 2010. – Vol.55, №6. – P.1770-1777.
11. Vainchenker W. New mutations and pathogenesis of myeloproliferative neoplasms / W. Vainchenker, F. Delhommeau, SN Constantinescu//Blood. – 2011. – Vol.118, №7 – P.1723–1735. DOI:10.1182/blood-2011-02-292102.
12. Tefferi A. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study / A. Tefferi, E. Rumi, G. Finazzi [et al.]//Leukemia. – 2013. – Vol.27. – P.1874-1881. DOI: 10.1038/leu.2013.163
13. Tefferi A. Genetic risk assessment in myeloproliferative neoplasms / A. Tefferi // Mayo Clinic proceedings. – 2017. – Vol.92,№8. – P.1283-1290. DOI: 10.1016/j.mayocp.2017.06.002
14. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion / T.Barbui, J. Thiele, H. Gisslinger [et al.] // Blood cancer J. – 2018. – Vol.8, №2. – P.15. DOI: 10.1038%2Fs41408-018-0054-y
15. Casini A. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management / A. Casini, P. Fontana, T.P. Lecompte // J. ThrombHaemost. - 2013 – Vol.11, №7. – P.1215-1227. DOI: 10.1111/jth.12265.
Review
For citations:
Aleksandrova T.N., Mulina I.I., Yadrikhinskaya V.N., Solovieva I.E., Terekhova L.D., Pavlova N.I., Kurtanov Kh.A. Clinical and epidemiological aspects of chronic myeloproliferative diseases in the RS (Ya). Yakut Medical Journal. 2019;(3):37-40. https://doi.org/10.25789/YMJ.2019.67.10
Views:
3
Email this article 